On Wednesday, Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s shares gained 3.53%, and closed at $66.52, hitting new 52-week high of $67.32, as on April 2, Teva Pharmaceutical and Xenon Pharmaceuticals Inc. (NASDAQ:XENE) declared that the first patient has been enrolled into the Phase 2b study designed to evaluate the safety and efficacy of the novel topically applied TV-45070, (4% and 8% w/w ointment) in patients with postherpetic neuralgia (PHN).
TV-45070 is a small molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, counting those that are expressed in the pain-sensing peripheral nervous system. It is being developed for the treatment of patients with various pain indications, counting neuropathic and osteoarthritis pain.
The Phase 2b clinical study in PHN is a randomized, double-blind, placebo controlled, multi-site study that will evaluate the safety and efficacy of topically applied TV-45070 ointment contrast with placebo.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The corporation operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX)’s shares jumped 3.53%, and settled at $205.96, during the last trading session on Wednesday, as on April 1, Salix Pharmaceuticals, Ltd. a wholly owned partner of Valeant Pharmaceuticals International, Inc. (VRX) declared that it offered a Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event, Fundamental Change Corporation Notice, Notice of Execution of Supplemental Indenture and Offer to Purchase to holders of its 1.5% Convertible Senior Notes due 2019, following the Indenture, dated as of March 16, 2012, by and between the Corporation and U.S. Bank National Association, as trustee.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The corporation offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
At the end of Wednesday’s trade, Brookdale Senior Living Inc. (NYSE:BKD)’s shares climbed 3.52%, and closed at $38.26, hitting new 52-week high of $39.89, as on April 1, Twenty Brookdale skilled nursing communities have received the highest possible overall rating of five stars from U.S. News & World Report in the magazine’s seventh annual Best Nursing Homes review. U.S. News awarded the “Best Nursing Home” designation to communities that received the highest rating in February2015 from Centers for Medicare and Medicaid Services (CMS), which sets and enforces federal requirements and standards for nursing homes certified to receive Medicare and Medicaid payments. The ratings are based on a community’s performance in care, safety, health inspections and staffing.
“Having 20 Brookdale communities receive the highest rating from CMS speaks volumes about our community associates who are dedicated to providing quality care to our residents,” said Kim Estes, senior vice president of clinical services. “As important as the rating system is, we encourage consumers to tour the skilled nursing facilities they are considering to get a firsthand understanding of the overall environment they offer.”
Brookdale Senior Living Inc. owns and operates senior living communities in the United States. It operates through five segments: Retirement Centers, Assisted Living, Ongoing Care Retirement Communities (CCRCs)Rental, Brookdale Ancillary Services, and Administration Services.
FireEye, Inc. (NASDAQ:FEYE), ended its Wednesday’s trading session with 3.28% gain, and closed at $41.22, after the leader in stopping today’s advanced cyber attacks, declared it will release financial results for its first quarter 2015 on Thursday, April 30, 2015 after the close of the U.S. markets. FireEye will host a conference call the same day at 5 p.m. ET (2 p.m. PT) to talk about the results.
FireEye, Inc., together with its auxiliaries, provides cybersecurity solutions for detecting, preventing, and resolving cyber-attacks. The corporation offers vector-specific appliance solutions that provide threat protection from network to endpoint for inbound and outbound network traffic that may contain sensitive information.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
